Nope, I was wrong. Forgot they confirmed no further trials needed in the annual report.
It was my thought though that that would be a catalyst for the sp, which has turned out to be wrong. Funny, with other companies issue clarity by the FDA has been reason for rerating (up or down).
reality check, page-4
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
